EUVIMEDEUVIMED entdecken
Crossref

Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents

Bin Jiang, Yijia Zheng, Tiezheng Xue, Jizhou Wu, Huijuan Song, Sheng Zhou, Yujing Li, Jiaqi Gong, Meng Wei, Xiaorui Ji, Meijiao Wei, Lujun Wang und 6 weitere

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.108355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Bin Jiang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Department of Phar…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Microtubules, Benzamides, Tubulin Modulators. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Hebei Provincial Natural Science Foundation, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMB5046, a microtubule inhibitor discovered by our team, served as the lead compound for designing a series of selenium-containing benzoates and benzamides. Among these, compound 2g emerged as a lead candidate, demonstrating potent antiproliferative activity. Mechanistic studies revealed that 2g bound to the colchicine site of tubulin, caused G2/M cell cycle arrest, and generated ROS. Notably, 2g exhibited exceptional efficacy in P-gp overexpressing MCF7/ADR and KBV200 cell lines, with drug-resistance indices (DRI) of 0.83 and 0.58, respectively, significantly outperforming colchicine (DRIs: 25.4 and 8.03) and paclitaxel (DRIs: 41.0 and 4.96). In an MCF-7 xenograft model, 2g (25 mg/kg, IP) achieved a tumor growth inhibition rate of 57.2 %, surpassing IMB5046 (47.6 %). To enhance solubility and pharmacokinetics, prodrug 2g-P was developed, showing 69 % bioavailability but reduced in vivo efficacy. Further investigation is warranted to elucidate the factors underlying the discrepancy, such as the efficiency of prodrug-to-drug conversion and intracellular accumulation of active 2g. In summary, our study not only identified a novel selenium-containing lead compound, but also provided important insights into prodrug design. These findings lay a solid foundation for the development of next-generation microtubule-targeting agents capable of overcoming drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMicrotubulesBenzamidesTubulin ModulatorsSeleniumOrganoselenium CompoundsHumansCell ProliferationDrug Screening Assays, AntitumorStructure-Activity RelationshipAnimalsMolecular StructureMiceDose-Response Relationship, DrugCell Line, TumorFemale

Stichwörter der Autor:innen

Colchicine binding siteIMB5046Microtubule-targeting agentsP-gp overexpressing cellsProdrug

Substanzen

Antineoplastic AgentsBenzamidesTubulin ModulatorsSeleniumOrganoselenium Compounds

Autor:innen und Institutionen

  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Sh…
  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
  • Department of Pharmacy, Medical Supplies Center of PLA General Hospital, China.
  • Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China. Electronic address: 18100956@hebmu.edu.cn.
  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: lvkai@imb.pumc.edu.cn.

Förderung

  • Natural Science Foundation of Beijing Municipality
  • Hebei Provincial Natural Science Foundation
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

Zitieren

APA

Jiang, B., Zheng, Y., Xue, T., Wu, J., Song, H., Zhou, S., Li, Y., Gong, J., Wei, M., Ji, X., Wei, M., Wang, L., Gong, J., Liu, M., Wang, A., Zhang, K., Lv, K., & Zheng, Y. (2025). Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108355

Vancouver

Jiang B, Zheng Y, Xue T, Wu J, Song H, Zhou S, et al. Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108355

BibTeX
@article{Jiang2025,
  author = {Jiang, Bin and Zheng, Yijia and Xue, Tiezheng and Wu, Jizhou and Song, Huijuan and Zhou, Sheng and Li, Yujing and Gong, Jiaqi and Wei, Meng and Ji, Xiaorui and Wei, Meijiao and Wang, Lujun and Gong, Jianhua and Liu, Mingliang and Wang, Apeng and Zhang, Kai and Lv, Kai and Zheng, Yanbo},
  title = {Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.108355}
}
Kostenlos starten →